Monashee Investment Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Monashee Investment Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-95,000	Closed	-$1.87M	–	71
2022 Q3	$1.87M	Sell	95,000 -145,000	-60%	-$2.91M	0.69%	24
2022 Q2	$4.2M	Buy	240,000 +150,000	+167%	+$2.35M	1.53%	2
2022 Q1	$1.47M	Sell	90,000 -5,000	-5%	-$68K	0.43%	22
2021 Q4	$1.55M	Buy	+95,000	New	+$1.35M	0.38%	33
2021 Q1	–	Sell	-272,949	Closed	-$4.33M	–	454
2020 Q4	$4.33M	Buy	+272,949	New	+$4.12M	0.57%	37

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Monashee Investment Management's KDNY Position: Q4 2022 in Review

Monashee Investment Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2022, closing a stake of 95,000 shares — an estimated $1.87M sold.

Monashee Investment Management first reported a position in KDNY in Q4 2020 and held it in 5 quarters. The position peaked at $4.33M in Q4 2020. 155 funds tracked by Wall St. Rank hold KDNY as of Q4 2022.

Monashee Investment Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Monashee Investment Management sold 95,000 Chinook Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $1.87M.
Monashee Investment Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
Monashee Investment Management's Chinook Therapeutics, Inc. Common Stock position peaked at $4.33M in Q4 2020.
155 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Monashee Investment Management's 13F filing for Q4 2022, filed 9 Feb 2023.